VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $402,296,129 | +2.1% | 7,891,254 | 0.0% | 7.92% | +6.4% |
Q2 2023 | $394,089,225 | +44.2% | 7,891,254 | +8.2% | 7.44% | +20.3% |
Q1 2023 | $273,276,200 | -2.7% | 7,291,254 | +24.5% | 6.19% | +8.6% |
Q4 2022 | $280,865,159 | +155.5% | 5,857,459 | +27.9% | 5.70% | +142.8% |
Q3 2022 | $109,949,000 | +10.3% | 4,581,203 | 0.0% | 2.35% | -11.7% |
Q2 2022 | $99,687,000 | -9.9% | 4,581,203 | 0.0% | 2.66% | +10.1% |
Q1 2022 | $110,636,000 | +9.7% | 4,581,203 | +8.0% | 2.41% | +35.7% |
Q4 2021 | $100,881,000 | +2.0% | 4,240,464 | +8.8% | 1.78% | +29.9% |
Q3 2021 | $98,863,000 | +13.6% | 3,896,865 | +0.8% | 1.37% | -1.9% |
Q2 2021 | $87,019,000 | +14.0% | 3,865,808 | 0.0% | 1.40% | +21.4% |
Q1 2021 | $76,350,000 | -22.6% | 3,865,808 | +4.2% | 1.15% | -16.5% |
Q4 2020 | $98,593,000 | -62.2% | 3,710,699 | -29.8% | 1.38% | -71.1% |
Q3 2020 | $260,915,000 | +50.4% | 5,283,818 | -3.7% | 4.77% | +41.1% |
Q2 2020 | $173,513,000 | – | 5,489,181 | – | 3.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 4,168,718 | $100,049,000 | 34.21% |
Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $45,299,000 | 18.86% |
Pivotal bioVenture Partners Investment Advisor LLC | 776,039 | $18,625,000 | 6.81% |
Kynam Capital Management, LP | 698,638 | $16,767,000 | 3.53% |
GREAT POINT PARTNERS LLC | 600,000 | $14,400,000 | 3.47% |
Frazier Life Sciences Management, L.P. | 1,547,405 | $37,138,000 | 2.86% |
Ghost Tree Capital, LLC | 360,000 | $8,640,000 | 2.42% |
RA Capital Management | 4,581,203 | $109,949,000 | 2.35% |
Opaleye Management Inc. | 190,000 | $4,560,000 | 1.88% |
TPG GP A, LLC | 3,285,504 | $78,852,000 | 1.29% |